Program Overview
Rabies remains a vaccine-preventable disease that is almost invariably fatal after clinical onset. Ending human deaths from dog-mediated rabies requires interrupting transmission within a region—not only treating individuals after exposure.
Population immunization of free-roaming dogs and wildlife is central to that goal. Even moderate campaign coverage can break local transmission chains when enough animals are protected during a single contact event.
Why One Dose Matters
Multi-dose schedules work in clinics where the same patient returns for follow-up visits. They do not work in the field: you cannot capture the same wild or stray animal every week for four separate injections.
Orion Biotech is developing a one-dose rabies vaccine centered on prefusion-stabilized rabies virus glycoprotein (RABV-G). The candidate is designed to deliver effective immunity during a single field contact—by injection, bait delivery, or other campaign-appropriate routes—so regional vaccination programs can reach animals that will never return for a booster.
The program builds on recombinant antigen design, adjuvant-enhanced immunogenicity, and established preclinical work in rabies vaccinology.
Evidence & Outlook
Key development readouts include rapid neutralizing antibody induction, durability, challenge protection, and practical advantages in stability and scalable manufacturing for campaign deployment. The team brings publication and patent experience in rabies vaccinology.
We welcome discussions with public-health agencies, veterinary partners, CDMOs, and research institutions pursuing responsible regional elimination goals.